Table 1 Baseline patient demographic and clinical characteristics (full analysis set)
| Â | csDMARDs plus denosumab (N = 21) | csDMARD therapy alone (N = 22) |
|---|---|---|
Female sex | 18 (85.7) | 20 (90.9) |
Age, years | 65.6 ± 8.5 | 65.0 ± 9.2 |
 ≥ 65 years | 12 (57.1) | 11 (50.0) |
Body mass index, kg/m2 | 22.94 ± 3.42 | 22.64 ± 4.48 |
Duration of rheumatoid arthritis, months | 162.3 ± 151.3 | 150.5 ± 129.0 |
 < 6 months | 1 (4.8) | 0 (0.0) |
 6 to < 36 months | 4 (19.0) | 3 (14.3) |
 ≥ 36 months | 16 (76.2) | 18 (85.7) |
Osteoporosis | 15 (71.4) | 11 (50.0) |
Prior fracture | 5 (23.8) | 5 (22.7) |
Medical history other than fracture | ||
 Knee arthroplasty | 1 (4.8) | 0 (0.0) |
 Tonsillectomy | 1 (4.8) | 0 (0.0) |
Bone erosion (HR-pQCT of 2–3 metacarpal heads) | 8 (38.1) | 13 (59.1) |
Anti-CCP antibody-positive | 16 (76.2) | 17 (77.3) |
Rheumatoid factor-positive | 17 (81.0) | 18 (81.8) |
Concomitant medications | ||
 Vitamin D and calcium | 21 (100.0) | 14 (63.6) |
 Bisphosphonates | 0 (0.0) | 4 (18.2) |
 Glucocorticoids | 10 (47.6) | 4 (18.2) |
csDMARDs | 21 (100.0) | 22 (100.0) |
 Methotrexate | 19 (90.5) | 16 (72.7) |
 Salazosulfapyridine | 7 (33.3) | 3 (13.6) |
 Tacrolimus hydrate | 1 (4.8) | 3 (13.6) |
 Iguratimod | 1 (4.8) | 2 (9.1) |
 Bucillamine | 0 (0.0) | 3 (13.6) |
DAS28-ESR | 3.064 ± 0.834 | 3.041 ± 0.879 |